MarginsXMarginsX
Home › Markets › Health Care › CELZ

Creative Medical Technology Holdings Inc. (CELZ)

CELZ trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5201
-1.51% on the day
Market cap
$4.0M
Nano cap
Revenue · 2025
$6K
-45.5% on 2024
Net income · 2025
-$6.0M
-99916.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1187953/000147793226001517/0001477932-26-001517-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCELZ on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001187953
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNV

Financials · 2025

LineValue
Revenue$6K
Net income-$6.0M
Operating income-$6.1M
Net margin-99916.8%
Operating margin-102380.2%
Revenue growth-45.5%
Cash$7.2M
Total assets$7.8M
P/E (computed)Net income was not positive
P/S (computed)658.6×

Warning signs

Cash runway
12.8 months
$6.8M cash at September 30, 2026
Share count, 1 year
+194.4%
2025-11-01 to 2026-11-06 · +449.7% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$6.8M cash; operating cash flow -$1.6M a quarter.Report 2026-09-30
Shares outstanding7,597,557 (2026-11-06); 2,580,532 a year earlier; 1,382,126 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-07-24
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-11-13
AuditorHaynie & Company, Salt Lake City, Utah, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$2.7M-$1.7M$6.8MNo debt tags$3K10-Q 2026-11-06
Q2 2026
2026-06-30
$0-$1.5M-$1.5M$8.7MNo debt tags$3K10-Q 2026-08-07
Q1 2026
2026-03-31
$0-$1.4M-$1.3M$5.7MNo debt tags$3K10-Q 2026-05-08
Q4 2025
2025-12-31
$3K-$1.9M-$1.9M$7.2MNo debt tags$6K10-K 2026-03-20
Q3 2025
2025-09-30
$0-$1.2M-$1.2M$5.4MNo debt tags$6K10-Q 2026-11-06
Q2 2025
2025-06-30
$0-$1.2M-$1.2M$6.6MNo debt tags$6K10-Q 2026-08-07
Q1 2025
2025-03-31
$3K-$1.6M-$1.6M$7.7MNo debt tags$14K10-Q 2026-05-08
Q4 2024
2024-12-31
$3K-$1.9M-$1.9M$5.9MNo debt tags$11K10-K 2026-03-20

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-08-03
Latest annual report
FORM 10-K/A
10-K/A2026-04-24
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-06
Latest current report
FORM 8-K
8-K2026-11-13
Latest proxyDEF 14A2026-11-10

Source: SEC EDGAR submissions feed, 412 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.1%
1 month-35.6%
3 months-57.4%
Year to date-73.1%
1 year-81.3%
From 52-week high-83.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CRISCuris Inc.$0.4358-2.07%$4.1M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M
SNTISenti Biosciences Holdings Inc.$0.1360-2.86%$5.2M
VIVSVivoSim Labs Inc.$0.1237-2.68%$2.5M
CLDICalidi Biotherapeutics Inc.$0.6023-3.15%$2.2M
INABIN8bio Inc.$0.8160-0.49%$8.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier